A renewed spotlight is forming around a group of small-cap healthcare companies as U.S. policy shifts toward accelerating research into psychedelic-based therapies for mental health disorders. Following a recent executive order aimed at expanding research pathways, companies below are drawing increased investor and industry attention as innovation and regulatory momentum converge.

Atai Life Sciences (NASDAQ: ATAI) Advancing Next-Generation Mental Health Therapies, is positioning itself at the forefront of psychedelic drug development through its Ata,Beckley platform, focused on rapid-acting and durable treatments for mental health disorders. The company’s pipeline includes BPL-003 (mebufotenin benzoate nasal spray) targeting treatment-resistant depression (TRD), currently in Phase 3 planning, alongside VLS-01 (DMT buccal film) and EMP-01 ((R)-MDMA HCl) in Phase 2 development. In parallel, the company is advancing non-hallucinogenic 5-HT2A receptor agonists, signaling a broader strategy to deliver scalable psychiatric treatments that can integrate into traditional healthcare systems.

Compass Pathways (NASDAQ: CMPS) Leading Psilocybin Clinical Development continues to advance psilocybin-based therapies through its COMP360 program, targeting treatment-resistant depression. The therapy has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Innovative Licensing and Access Pathway (ILAP) designation in the United Kingdom. These milestones highlight the program’s potential as a first-in-class treatment and position the company at the center of evolving regulatory frameworks for psychedelic medicine.

Psyence Biomedical (NASDAQ: PBM) Building Infrastructure for Ibogaine-Based Therapies is strengthening its position in the emerging ibogaine market as regulatory and clinical interest expands globally. Through its collaboration with PsyLabs, the company has established an integrated, GMP-compliant manufacturing platform spanning sourcing, extraction, purification, and pharmaceutical production. With direct access to raw materials in Africa, Psyence Biomedical is focused on ensuring traceability, supply continuity, and sustainability—key components as ibogaine-based therapies move closer to structured clinical evaluation and potential commercialization.

ENDRA Life Sciences (NASDAQ: NDRA) Supporting Clinical Infrastructure Growth while not a psychedelic drug developer, is increasingly emerging as a critical player in the healthcare infrastructure supporting next-generation therapies, particularly as the rapid expansion of GLP-1 treatments places added pressure on clinical trial capacity and diagnostic scalability. Its TAEUS® liver imaging technology is designed to measure liver fat and enable real-time clinical decision-making for metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH—conditions impacting more than two billion people globally. As demand for efficient, non-invasive diagnostics continues to rise alongside therapeutic innovation, ENDRA’s platform is gaining relevance across multiple areas of care.

Notably, the company has initiated a review of strategic alternatives aimed at expanding and strengthening long-term growth and commercialization pathways, potentially extending beyond its current core focus. With both technological and strategic initiatives underway, market observers may anticipate further developments and announcements as ENDRA continues to position itself within a rapidly evolving healthcare landscape. Momentum in the stock has also reflected growing investor interest, with ENDRA Life Sciences (NASDAQ: NDRA) closing at $6.40 on approximately $488,000 in dollar volume on Friday, April 19, 2026—marking a 96.3% gain over the past 30 days.

Policy Shift Signals Broader Sector Opportunity

The executive order accelerating psychedelic research reflects a broader shift toward addressing mental health through innovative, science-driven approaches. As regulatory pathways evolve, companies such as Atai Life Sciences (NASDAQ: ATAI), Psyence Biomedical (NASDAQ: PBM), and Compass Pathways (NASDAQ: CMPS) may benefit from increased clinical momentum and clearer development frameworks. At the same time, infrastructure-focused companies like ENDRA Life Sciences (NASDAQ: NDRA) could see indirect tailwinds as demand for clinical trial support technologies grows.

Outlook

As capital flows into emerging healthcare innovation themes, these small-cap companies are increasingly being monitored for their roles in shaping the future of mental health treatment and clinical development.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com